- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02847455
Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients
July 25, 2016 updated by: Livzon Pharmaceutical Group Inc.
Efficacy and Safety of Ilaprazole for Acute Duodenal Ulcer: A Randomized,Double-Blind,Rabeprazole-Controlled,Multicenterand Phase3 Trial in China in China
Patients with endoscopically diagnosed active duodenal ulcer disease were enrolled in a randomized, double-blind, parallel and dose-ranging trial.
They were randomly assigned into three groups to be treated for up to four weeks and be seen at week 1, 2 and 4: three of ilaprazole, 5, 10 mg/day, and one of Rabeprazole 10 mg/day as positive control.
The primary endpoint was the ulcer healing rate at week 4. Healing of ulcer was determined by its resolution from active to scarring stage.
Symptoms relief was evaluated as secondary end points by using a graded score.
Safety and tolerability were evaluated on basis of clinical assessments.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The primary endpoint was the healing rate of ulcers, which based on post-treatment (week 4) endoscopic changes in stage of the ulcer relative to baseline (week 0) levels.
Stages of the ulcers were endoscopically assessed according to the degree of ulceration, regenerating epithelialization, and scarring, which was defined as follows: A stage (active stage, A1 & A2) where A1 stage is more severe than A2 stage, H stage (healing stage, H1 & H2) where H2 stage is better than H1 stage, and S stage (scarring stage, S1 (red scar) & S2 (white scar)) where S stage is the best stage in the three stages and S2 stage is better than S1.Healing of ulcer is deemed successful if an ulcer in A stage resolved to S stage at the end of the treatment period, regardless of S1 or S2.
When endoscopy demonstrated successful ulcer healing, study medication was discontinued.
Patients returned at week 2, and if unhealed further endoscopic assessment would be done at week 4. Secondary endpoints included post-treatment resolution of related gastrointestinal symptoms such as upper abdominal pain, heartburn, acid regurgitation, nausea & vomiting, eructation, and increased flatus.
These symptoms were recorded on a scale ranging from 0 to 3(0=none, 1=mild, 2=moderate, 3=severe) at baseline, week 1, 2, and 4. Resolution of symptoms were defined as "excellence", "effective", "improved", or "ineffective" relative to baseline levels, of which complete symptom relief or complete absence of the symptom without recurrence was deemed as "excellence".
Safety assessments based mainly on the occurrence, frequency, and severity of adverse events, which were monitored throughout the duration of the study, and also based on comprehensive indexes, including physical examination, electrocardiography, and routine laboratory investigations, which were performed at baseline and repeated at the end of the treatment period.
For all adverse events, where necessary, patients were withdrawn from the study.
Study Type
Interventional
Enrollment (Actual)
408
Phase
- Phase 2
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Consenting patients were eligible for enrollment if they:
- were 18-65 years of age,
- had endoscopically diagnosed active duodenal ulcers within the previous 72 hours,
- the number of ulcers was at least one, but no more than two with the larger diameter 0.3-2.0cm.
Exclusion Criteria:
- Patients were ineligible if they:
- had cancerous or complex ulcers, Zollinger-Ellison syndrome, esophageal erosion or ulcer, varices of esophagus or fundus of stomach, or pyloric stenosis,
- had a known history of gastric acid suppression operation, esophageal operation or peptic operation other than simple closure of perforation,
- had severe complications (e.g., pyloric obstruction, active bleeding under endoscope), severe other diseases of digestive tract such as Crohn's disease and ulcerative colitis, and severe other systemic diseases,
- were female patients who were breast feeding, pregnant, or intended to become pregnant during the study,
- had taken proton pump inhibitors within the 5 days or for more than three consecutive days within the two weeks immediately preceding start of study drug,
- participated in a clinical trial with an investigational drug or device within the past three months,
- had hypersensitivity or idiosyncratic reaction to omeprazole or any other benzimidazole,
- had alcoholic intemperance, drug addiction or any other improper habits.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 10 mg ilaprazole
|
Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with two placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
|
Experimental: 5 mg ilaprazole
|
One 5-mg ilaprazole tablet (Livzon Pharm Group Inc., China) together with three placebo tablets and one placebo capsule in a package being taken orally each
|
Active Comparator: 10mg Rabeprazole
|
one 10-mg Rabeprazole tablets together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary endpoint was the healing rate of ulcers, which based on post-treatment (week 4) endoscopic changes in stage of the ulcer relative to baseline (week 0) levels.
Time Frame: week 4
|
week 4
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Secondary endpoints included post-treatment resolution of related gastrointestinal symptoms such as upper abdominal pain, heartburn, acid regurgitation, nausea & vomiting, eructation, and increased flatus.
Time Frame: week 4
|
week 4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2008
Primary Completion (Actual)
October 1, 2009
Study Registration Dates
First Submitted
July 25, 2016
First Submitted That Met QC Criteria
July 25, 2016
First Posted (Estimate)
July 28, 2016
Study Record Updates
Last Update Posted (Estimate)
July 28, 2016
Last Update Submitted That Met QC Criteria
July 25, 2016
Last Verified
July 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Gastrointestinal Diseases
- Stomach Diseases
- Intestinal Diseases
- Peptic Ulcer
- Duodenal Diseases
- Ulcer
- Duodenal Ulcer
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Gastrointestinal Agents
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Rabeprazole
Other Study ID Numbers
- LIVZON-IY-DU-0808.0
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Duodenal Ulcer
-
TakedaCompleted
-
TakedaCompletedGastric Ulcers | Duodenal UlcersJapan
-
TakedaCompletedGastric Ulcers | Duodenal UlcersJapan
-
Sihuan Pharmaceutical Holdings Group Ltd.Unknown
-
The Catholic University of KoreaSt Vincent's Hospital; Bucheon St. Mary's HospitalUnknown
-
GlaxoSmithKlinePiramal Clinical Research (Hyderabad, India)Completed
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownBleeding Gastric Ulcer | Bleeding Duodenal UlcerChina
-
The Third Xiangya Hospital of Central South UniversityLivzon Pharmaceutical Group Inc.; Yung Shin Pharm. Ind. Co., Ltd.CompletedDuodenal Ulcer Due to Helicobacter PyloriChina
-
B.P. Koirala Institute of Health SciencesCompletedPerforated Duodenal UlcerNepal
-
Sihuan Pharmaceutical Holdings Group Ltd.Completed
Clinical Trials on 5 mg ilaprazole
-
Livzon Pharmaceutical Group Inc.Completed
-
Livzon Pharmaceutical Group Inc.UnknownGastroesophageal Reflux Disease
-
Il-Yang Pharm. Co., Ltd.CompletedNon-erosive Reflux DiseaseKorea, Republic of
-
Yonsei UniversityCompletedGastrointestinal Subepithelial TumorsKorea, Republic of
-
Il-Yang Pharm. Co., Ltd.CompletedHelicobacter InfectionsKorea, Republic of
-
Livzon Pharmaceutical Group Inc.Completed
-
PfizerCompleted
-
Il-Yang Pharm. Co., Ltd.Not yet recruitingPeptic UlcerKorea, Republic of
-
Anesiva, Inc.CompletedTotal Knee Arthroplasty (Replacement)United States
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruiting